Tozuleristide(BLZ-100)在成人胶质瘤中的1期安全性、药代动力学与荧光成像研究
该1期剂量递增研究纳入17例疑似胶质瘤成人,术前3至29小时单次静脉给予Tozuleristide 3至30 mg,评估安全性、药代动力学及荧光成像。未观察到剂量限制性毒性,无不良事件被认为与药物相关;9 mg及以上剂量终末血清半衰期约30分钟。高、低级别胶质瘤均检测到荧光信号,高级别肿瘤荧光强度通常更高,且高级别肿瘤信号强度随剂量增加而增加。
要点
- Tozuleristide在3至30 mg剂量范围内安全性良好,无剂量限制性毒性。
- 9 mg及以上剂量终末血清半衰期约30分钟。
- 高、低级别胶质瘤均可见荧光信号,高级别肿瘤信号更强且随剂量增加。
核心结论
- Tozuleristide在最高30 mg剂量下安全性良好,其荧光成像可能有助于胶质瘤的荧光引导手术。
研究设计与样本
- 1期剂量递增研究,17例疑似胶质瘤成人接受单次静脉Tozuleristide 3至30 mg,术前3至29小时给药。
主要发现
- 17例受试者接受3至30 mg剂量,未观察到剂量限制性毒性,无不良事件被认为与Tozuleristide相关。
- 9 mg及以上剂量终末血清半衰期约30分钟。
- 高、低级别胶质瘤均检测到荧光信号,高级别肿瘤荧光强度通常高于低级别肿瘤。
- 高级别肿瘤中信号强度随Tozuleristide剂量增加而增加,与给药至手术的时间无关。
关键数值与推荐
- 给药剂量范围为3至30 mg,单次静脉给药。
- 给药时间为术前3至29小时。
- 9 mg及以上剂量终末血清半衰期约30分钟。
临床怎么用
- Tozuleristide在3至30 mg剂量下可用于胶质瘤荧光引导手术的成像探索,安全性支持进一步研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Fluorescence-guided surgery (FGS) can improve extent of resection in gliomas. Tozuleristide (BLZ-100), a near-infrared imaging agent composed of the peptide chlorotoxin and a near-infrared fluorophore indocyanine green, is a candidate molecule for FGS of glioma and other tumor types. OBJECTIVE: To perform a phase 1 dose-escalation study to characterize the safety, pharmacokinetics, and fluorescence imaging of tozuleristide in adults with suspected glioma. METHODS: Patients received a single intravenous dose of tozuleristide 3 to 29 h before surgery. Fluorescence images of tumor and cavity in Situ before and after resection and of excised tissue ex Vivo were acquired, along with safety and pharmacokinetic measures. RESULTS: A total of 17 subjects received doses between 3 and 30 mg. No dose-limiting toxicity was observed, and no reported adverse events were considered related to tozuleristide. At doses of 9 mg and above, the terminal serum half-life for tozuleristide was approximately 30 min. Fluorescence signal was detected in both high- and low-grade glial tumors, with high-grade tumors generally showing greater fluorescence intensity compared to lower grade tumors. In high-grade tumors, signal intensity increased with increased dose levels of tozuleristide, regardless of the time of dosing relative to surgery. CONCLUSION: These results support the safety of tozuleristide at doses up to 30 mg and suggest that tozuleristide imaging may be useful for FGS of gliomas.
引用
- Patil CG, Walker DG, Miller DM, et al. Phase 1 Safety, Pharmacokinetics, and Fluorescence Imaging Study of Tozuleristide (BLZ-100) in Adults With Newly Diagnosed or Recurrent Gliomas. Neurosurgery. 2019. PMID: 31069381. doi:10.1093/neuros/nyz125
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。